Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone
Phase 2RecruitingDevelopment Stage
The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Jul 31, 2024 → Mar 31, 2027
About Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone
Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06500247. Target conditions include The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06500247 | Phase 2 | Recruiting |
Competing Products
5 competing products in The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural saline | Johnson & Johnson | Pre-clinical | 23 |
| Letrozole | Novartis | Approved | 85 |
| Denosumab | Amgen | Phase 3 | 76 |
| Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil | Akeso | Phase 2 | 51 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 82 |